Discover resources for ultrasensitive blood biomarker detection
Stay up to date with our latest posters, case studies, events, and blogs.
Development of an ultrasensitive, scalable Solid Phase Ligation Assay with Single wasH (SPLASH) based immunoassay for the quantitation of LRRK2
Presented at AD/PD 2026
Multi-platform Quantitation Of Alzheimer’s Disease Biomarkers Using A Multiplex Assay Compatible With qPCR and dPCR
Presented at AD/PD 2026
Simultaneous Quantitation of pTau-217, Aβ42, NfL, and GFAP in Plasma Using a Novel Multiplex Assay for Alzheimer’s Disease Staging and Monitoring
Presented at AD/PD 2026
Absolute quantitation of protein enabled by digital proximity ligation assay to enhance quality control of protein reference material
Presented at AAIC 2025
Flexible assay platform for the quantitation of blood-based biomarkers for early detection of Alzheimer’s Disease
Presented at AAIC 2025
Scalable ultrasenstive quantification of blood-based biomarkers for Alzheimer’s Disease
Presented at ADPD 2025
Multiplexed Biomarker Profiling of Alzheimer's Disease Samples
Discover how Taudia’s five-plex SPLASH™ assay enables simultaneous quantitation of pTau-217, Aβ42, Aβ40, NfL, and GFAP from a single plasma sample—delivering high sensitivity, reduced variability, and scalable workflows for Alzheimer’s disease staging and monitoring.
Single-well multiplexing: Quantify multiple proteins from the same sample without sacrificing performance.
Learn how SPLASH™ single-well multiplexing provides accurate duplex quantitation of neurodegenerative biomarkers using the same simple workflow as singleplex assays—allowing researchers to measure multiple proteins from one sample without sacrificing performance.
A Novel Dried Plasma Spot (DPS)-Based Workflow for Quantification of Alzheimer's Disease Diagnostic Biomarkers
Explore a novel DPS-based workflow combining ambient-stable sample collection with SPLASH™ ultrasensitive detection to quantify pTau-217 and Aβ42—offering a practical, scalable path to decentralized Alzheimer’s disease screening and longitudinal monitoring.
Blood-Based Biomarker’s for Alzheimer’s: Impact on Clinical Trial Screening
Learn how Taudia’s single-wash SPLASH platform enables fast, accessible, and ultrasensitive blood-based biomarker testing to transform Alzheimer’s diagnosis and accelerate therapeutic development
AD is a growing public health challenge, with the number of affected Americans projected to reach 8.5 million by 2030...